Navigation Links
Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
Date:1/26/2012

PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc.- Florida has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Watson's generic versions of Mallinckrodt's Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets.  Mallinckrodt filed its lawsuit on December 10, 2010 in the United States District Court for the District of New Jersey following Watson's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its product in the 8 mg, 12 mg, and 16 mg dosage strengths.
Under terms of the settlement agreement, Mallinckrodt has granted Watson a royalty-free license to U.S. patents relating to Exalgo®.  Watson will have the right to launch its bioequivalent products on November 15, 2013.  Other details of the settlement were not disclosed.

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the generic version of Exalgo® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-h
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... FALLS CHURCH, Va., April 19, 2011 Technology Catalysts ... announced that research on cancer trends and development has ... a variety of cancers that currently have ineffective treatments. ... is forecast to approach $3 billion in 2015. ...
... April 19, 2011 Symmetry Medical Inc. (NYSE: ... to the global orthopaedic device industry and other medical ... its operations in a matrix structure to strengthen quality ... businesses will now report directly to Thomas J. Sullivan, ...
Cached Medicine Technology:Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015 2Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015 3Symmetry Medical Centralizes Businesses Under CEO 2Symmetry Medical Centralizes Businesses Under CEO 3Symmetry Medical Centralizes Businesses Under CEO 4
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on ... review today examining the current state of knowledge of ... for improved global surveillance strategies to combat the emergence ... Ebola in West Africa that has claimed the lives ... Liberia. According to the World Health Organization (WHO), ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... insulin resistance and high blood pressure begin as early ... measured obesity, insulin resistance, blood pressure and cholesterol levels ... the young people were 13 and again when they ... mass index (BMI) calculation. BMI is the person's weight ...
... is being tested against cervical cancer. Human papilloma virus ... but not everyone with the virus develops the cancer. ... and causes 300,000 deaths. If it is diagnosed and ... survival rate. // ,Doctors at Britain's Cancer ...
... body to the ageing process and may increase the ... and diabetes, researchers have found. ,These days, the average ... more developed countries has decreased from nine hours to ... increased demands of work and more leisure activities. ...
... who work nightshifts are more prone to develop breast cancer. ... worked during the nights for up to three years were ... did not work at night. ,And the risk increased to ... three years. ,The results of the study, carried ...
... Women who have irregular or very long menstrual cycles ... such menstrual abnormalities needn't panic because the risk can ... exercise and weight control. // ,Menstrual cycles ... be markers for some sort of underlying metabolic abnormality. ...
... study, cycling has shown a beneficial effect in treating sexual ... produce sexual dysfunction in men because blood flow is restricted, ... an erection. The problem is that many of these men ... medication for heart failure. ,Researchers in France reported ...
Cached Medicine News:Health News:Heart disease starts early 2Health News:Deprived sleep leads to ageing 2
... an elastic belt to help lift the weight ... Apron features all around protection to cover you ... wearing and removing a breeze. ,For additional back ... - they reduce pressure on the vertebrae and ...
... a 2 adjustable belt buckle. You adjust once ... Apron off your shoulders. And now theres our ... female anatomy. ,For additional back support try one ... pressure on the vertebrae and help lift the ...
StelKast's Proven™ Knee System is a long term high quality solution based on a clinically proven and successful design....
... TC-PLUS Solution tricompartmental total knee prosthesis stems ... arthroplasty. State-of-the-art design and manufacturing technologies have ... biomechanical function as well as a favorable ... insert to keep wear to a minimum. ...
Medicine Products: